REG-Syncona Limited: Update on Nightstar proposed NASDAQ IPO <Origin Href="QuoteRef">SYNCS.L</Origin>

SynconaAnnouncement

15/09/2017 13:05

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSE OF ARTICLE 7 OF
THE MARKET ABUSE REGULATION (EU) NO.596/2014

Syncona Limited

Update on Nightstar proposed NASDAQ IPO

15 September 2017

Syncona Ltd (“Syncona”), a leading healthcare company focused on investing
in and building global leaders in life science, today notes that its portfolio
company NightstaRx Limited (which has been reorganised as Nightstar
Therapeutics plc) (“Nightstar”) has filed an amended Form F-1 with the
U.S. Securities and Exchange Commission in respect of its proposed initial
public offering (“IPO”) in the United States of its American Depositary
Shares (“ADSs”) representing ordinary shares (available on the SEC’s
EDGAR database).

The amended Form F-1 filing states an expected pricing range for the proposed
IPO of US$13.00 – $15.00 per ADS, with each ADS representing one ordinary
share. This would represent an increase in value of Syncona’s current
shareholding in Nightstar (compared to the 31 July 2017 sterling holding
value) of £41.5 – £58.3 million 1  (6.3p-8.8p(1) per Syncona share).

Syncona has indicated an interest in purchasing ADSs in the IPO, subject to
agreement with the underwriters. The proposed maximum aggregate offering
amount specified in the filing is US$92.46 million, which assumes that the
public offering price is at the top of the range and includes the 15% option
to that is proposed to be granted to the underwriters to cover
over-allotments..

A further announcement will be made in due course.

This press release does not constitute an offer to sell or the solicitation of
an offer to buy securities, and shall not constitute an offer, solicitation or
sale in any jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities laws of
that jurisdiction.

The securities referred to in this release are to be offered only by means of
a prospectus. When available, copies of the preliminary prospectus can be
obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus
Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone
at (877) 547-6340, or by email at Prospectus_Department@Jefferies.com; Leerink
Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor,
Boston, MA 02110, or by telephone at (800) 808-7525 ext. 6132, or by email at
Syndicate@Leerink.com; or BMO Capital Markets Corp., Attention: Equity
Syndicate Department, 3 Times Square, New York, NY 10036, or by telephone at
(800) 414-3627, or by email at bmoprospectus@bmo.com.

 ENDS 

Enquiries

Syncona Ltd
Siobhan Weaver
Tel: +44 (0) 20 7611 2031

Tulchan Communications
Martin Robinson
Tel: +44 (0) 207 353 4200

About Syncona:

Syncona is a leading FTSE250 healthcare company focused on investing in and
building global leaders in life science. Our vision is to deliver
transformational treatments to patients in truly innovative areas of
healthcare while generating superior returns for shareholders. Our current
investment portfolio consists of seven high quality companies in life science
and a leading range of fund investments.  We seek to partner with the best,
brightest and most ambitious minds in science to build globally competitive
businesses. We are established leaders in gene therapy, cell therapy and
advanced diagnostics, and focus on delivering dramatic efficacy for patients
in areas of high unmet need.

Our market leading funds portfolio seeks to generate superior returns by
investing in long only and alternative investment funds. This represents a
productively deployed evergreen funding base which enables us to take a long
term approach to investing in life sciences as we target the best new
opportunities and support our existing portfolio companies to grow and
succeed.

Syncona is aligned with two of the premium charitable funders in UK science,
the Wellcome Trust, original founder of Syncona, and Cancer Research UK, both
of which are significant shareholders in our business.  We make a donation of
0.3% of Net Asset Value to a range of charities each year.

About Nightstar

Nightstar is a leading clinical-stage gene therapy company focused on
developing and commercializing novel one-time treatments for patients
suffering from rare inherited retinal diseases that would otherwise progress
to blindness. 

 1  As at 14 September 2017 foreign exchange rates 



Copyright (c) 2017 PR Newswire Association,LLC. All Rights Reserved